| Segment Information | 13. SEGMENT INFORMATION
We operate in one business segment, which primarily focuses on the development and commercialization of human therapeutics for life threatening diseases. All products are included in one segment because our major products, Atripla, Truvada and Viread, which together accounted for substantially all of our total product sales for the three and nine months ended September 30, 2011 and 2010, have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.
Product sales consisted of the following (in thousands):
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
|
|
Antiviral products: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Atripla |
|
$ |
794,699 |
|
|
$ |
742,692 |
|
|
$ |
2,361,203 |
|
|
$ |
2,151,368 |
|
|
Truvada |
|
|
744,727 |
|
|
|
668,741 |
|
|
|
2,129,139 |
|
|
|
1,968,222 |
|
|
Viread |
|
|
192,887 |
|
|
|
184,263 |
|
|
|
546,999 |
|
|
|
541,121 |
|
|
Hepsera |
|
|
35,631 |
|
|
|
47,519 |
|
|
|
112,383 |
|
|
|
156,977 |
|
|
Emtriva |
|
|
7,667 |
|
|
|
6,696 |
|
|
|
20,975 |
|
|
|
20,597 |
|
|
Complera |
|
|
19,044 |
|
|
|
— |
|
|
|
19,044 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total antiviral products |
|
|
1,794,655 |
|
|
|
1,649,911 |
|
|
|
5,189,743 |
|
|
|
4,838,285 |
|
|
AmBisome |
|
|
82,241 |
|
|
|
75,132 |
|
|
|
249,372 |
|
|
|
230,355 |
|
|
Letairis |
|
|
78,954 |
|
|
|
60,446 |
|
|
|
214,765 |
|
|
|
176,293 |
|
|
Ranexa |
|
|
81,983 |
|
|
|
60,312 |
|
|
|
236,353 |
|
|
|
172,015 |
|
|
Other products |
|
|
28,026 |
|
|
|
19,758 |
|
|
|
78,792 |
|
|
|
42,735 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total product sales |
|
$ |
2,065,859 |
|
|
$ |
1,865,559 |
|
|
$ |
5,969,025 |
|
|
$ |
5,459,683 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes total revenues from external customers and collaboration partners by geographic region (in thousands). Product sales and product-related contract revenues are attributed to countries based on ship-to location. Royalty and non-product related contract revenues are attributed to countries based on the location of the collaboration partner.
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
|
|
United States |
|
$ |
1,182,181 |
|
|
$ |
1,071,770 |
|
|
$ |
3,362,596 |
|
|
$ |
3,124,137 |
|
|
Outside of the United States: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Switzerland |
|
|
32,846 |
|
|
|
53,535 |
|
|
|
141,467 |
|
|
|
414,618 |
|
|
France |
|
|
154,684 |
|
|
|
126,485 |
|
|
|
437,602 |
|
|
|
376,564 |
|
|
Spain |
|
|
127,102 |
|
|
|
101,421 |
|
|
|
376,409 |
|
|
|
338,706 |
|
|
United Kingdom |
|
|
129,978 |
|
|
|
105,186 |
|
|
|
373,604 |
|
|
|
322,885 |
|
|
Italy |
|
|
93,082 |
|
|
|
78,395 |
|
|
|
302,658 |
|
|
|
261,519 |
|
|
Germany |
|
|
98,155 |
|
|
|
70,077 |
|
|
|
269,072 |
|
|
|
195,084 |
|
|
Other European countries |
|
|
128,570 |
|
|
|
177,356 |
|
|
|
430,507 |
|
|
|
509,050 |
|
|
Other countries |
|
|
175,062 |
|
|
|
153,431 |
|
|
|
491,092 |
|
|
|
408,170 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues outside of the United States |
|
|
939,479 |
|
|
|
865,886 |
|
|
|
2,822,411 |
|
|
|
2,826,596 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
$ |
2,121,660 |
|
|
$ |
1,937,656 |
|
|
$ |
6,185,007 |
|
|
$ |
5,950,733 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a % of total revenues):
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
September 30, |
|
|
Nine Months Ended
September 30, |
|
| |
|
2011 |
|
|
2010 |
|
|
2011 |
|
|
2010 |
|
|
Cardinal Health, Inc. |
|
|
18 |
% |
|
|
17 |
% |
|
|
17 |
% |
|
|
17 |
% |
|
McKesson Corp. |
|
|
15 |
% |
|
|
14 |
% |
|
|
15 |
% |
|
|
14 |
% |
|
AmerisourceBergen Corp. |
|
|
13 |
% |
|
|
13 |
% |
|
|
13 |
% |
|
|
12 |
% |
|